Patents by Inventor Mortimer M. Civan

Mortimer M. Civan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090258836
    Abstract: Provided are methods for reducing intraocular pressure in an individual having an ocular disorder causing elevated intraocular pressure, such as glaucoma. The method comprises administering to the individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an A3 subtype adenosine receptor (A3AR) antagonist, including dihydropyridine, pyridine, pyridinium salt or triazoloquinazoline, and derivatives thereof expressly having A3AR antagonist activity, including, e.g., the nucleoside-based A3AR antagonist, MRS-3820. Further provided is a method for ensuring the delivery of a topically administered therapeutic composition for reducing intraocular pressure, wherein the method expressly requires physically opening a channel through the corneal barrier of the patient's eye by a microneedle or micropipette to permit transport of the topical composition to the anterior chamber of the eye.
    Type: Application
    Filed: April 6, 2009
    Publication date: October 15, 2009
    Inventors: Mortimer M. Civan, Kenneth A. Jacobson, Marcel Y. Avila, Richard Stone
  • Publication number: 20030153626
    Abstract: A method for decreasing intraocular pressure by administering an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen. These agents, by inhibiting influx or promoting efflux of aqueous humor, can be used to treat glaucoma.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 14, 2003
    Inventors: Mortimer M. Civan, Richard A. Stone, Claire H. Mitchell, Kenneth A. Jacobson
  • Publication number: 20030083227
    Abstract: Provided is a method for modulating, controlling or regulating intraocular pressure and secretion of the aqueous humor of the eye, in particular for treating or reducing elevated intraocular pressure or secretion, e.g., related to glaucomas. Selected combined drug therapy effectively and synergistically modulates intraocular pressure by either (1) double-blocking the uptake step, wherein both transporters in the first (entry step) of aqueous humor formation are blocked or inhibited; or (2) blocking the entry and exit steps, wherein the sodium-hydrogen (Na+/H+) exchanger underlying the entry step is blocked or inhibited, and also lowering or reducing the activity of the chloride (Cl−) channels involved in the second (exit) step of aqueous humor formation. By combining the selected drugs or compounds to produce a combined or synergistic modulating effect, control of IOP is achieved at very low concentrations, with fewer adverse side-effects on the patient.
    Type: Application
    Filed: August 13, 2002
    Publication date: May 1, 2003
    Inventors: Mortimer M. Civan, Kenneth A. Jacobson, Anthony D.C. MacKnight, Claire H. Mitchell, Richard A. Stone
  • Patent number: 6528516
    Abstract: This invention relates to a method of decreasing intraocular pressure by administrating an A3 subtype adenosine receptor antagonist, a calmodulin antagonist or an antiestrogen such as tamoxifen.
    Type: Grant
    Filed: May 4, 2001
    Date of Patent: March 4, 2003
    Assignee: Trustees of the University of Pennsylvania, The Center for Technology Transfer
    Inventors: Mortimer M. Civan, Richard A. Stone, Claire H. Mitchell, Kenneth A. Jacobson